Dorsey Wright & Associates Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR)

Dorsey Wright & Associates acquired a new position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 5,769 shares of the biotechnology company's stock, valued at approximately $2,067,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Tri Locum Partners LP purchased a new position in United Therapeutics during the second quarter worth $15,959,000. Renaissance Technologies LLC lifted its position in shares of United Therapeutics by 1.1% during the second quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company's stock worth $692,748,000 after purchasing an additional 22,978 shares during the last quarter. Bridgewater Associates LP lifted its position in shares of United Therapeutics by 384.3% during the third quarter. Bridgewater Associates LP now owns 61,755 shares of the biotechnology company's stock worth $22,130,000 after purchasing an additional 49,003 shares during the last quarter. Vontobel Holding Ltd. lifted its position in shares of United Therapeutics by 90.4% during the third quarter. Vontobel Holding Ltd. now owns 1,664 shares of the biotechnology company's stock worth $596,000 after purchasing an additional 790 shares during the last quarter. Finally, Glenmede Trust Co. NA lifted its position in shares of United Therapeutics by 6.4% during the third quarter. Glenmede Trust Co. NA now owns 68,605 shares of the biotechnology company's stock worth $24,585,000 after purchasing an additional 4,145 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. HC Wainwright lifted their target price on United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. Argus lifted their target price on United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday, October 17th. Jefferies Financial Group lifted their price objective on United Therapeutics from $315.00 to $432.00 and gave the company a "buy" rating in a report on Monday, September 23rd. Finally, LADENBURG THALM/SH SH lifted their price objective on United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $370.86.

Insider Transactions at United Therapeutics

In related news, COO Michael Benkowitz sold 15,000 shares of the company's stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $401.44, for a total value of $6,021,600.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at $1,034,510.88. This represents a 85.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Christopher Causey sold 510 shares of the company's stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $376.63, for a total value of $192,081.30. Following the completion of the sale, the director now owns 3,675 shares in the company, valued at approximately $1,384,115.25. This represents a 12.19 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 127,142 shares of company stock worth $47,460,419. Insiders own 11.90% of the company's stock.

United Therapeutics Price Performance

United Therapeutics stock traded down $4.70 during trading hours on Friday, reaching $369.67. The stock had a trading volume of 199,272 shares, compared to its average volume of 303,476. The company has a market cap of $16.51 billion, a price-to-earnings ratio of 16.23, a PEG ratio of 1.07 and a beta of 0.54. The business's 50 day moving average price is $369.14 and its 200-day moving average price is $339.06. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping analysts' consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same quarter in the previous year, the firm earned $5.38 earnings per share. The company's revenue was up 22.9% on a year-over-year basis. On average, sell-side analysts forecast that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.